Objectives: Myocardial infarction (MI) remains a leading cause of global mortality, and the inhibition of ferroptosis has cardioprotective potential. Taoren Honghua Jian (TRHHJ) has been used clinically to improve cardiovascular disorders. However, whether TRHHJ inhibits cardiomyocyte ferroptosis and ameliorates myocardial damage after MI requires further investigation. This study aimed to assess the ferroptosis-inhibiting effects of TRHHJ on post-MI myocardial injury and its underlying mechanisms.
Methods: In vivo MI models were established via left anterior descending coronary artery ligation, and the cardioprotective effects of TRHHJ were assessed by echocardiography and histopathology combined with ferroptosis biomarker detection and Nrf2 signaling protein analysis. In vitro, erastin induced ferroptosis in H9C2 cells, and the anti-ferroptotic effects of TRHHJ was evaluated using the MTT assay, ferroptosis markers, and Nrf2 signaling analysis. Mechanistically, Nrf2 inhibitor and knockout mice were used for validation.
Results: TRHHJ suppressed cardiomyocyte ferroptosis, reduced myocardial damage, and improved cardiac function in post-MI mice by activating the Nrf2 signaling pathway in vivo. TRHHJ enhanced cell viability and inhibited erastin-induced ferroptosis in H9C2 cells by increasing Nrf2 level and activating downstream signaling in vitro. Inhibition or knockout of Nrf2 partially abolished these protective effects.
Conclusions: TRHHJ inhibits cardiomyocyte ferroptosis and improves myocardial damage after MI through activation of Nrf2 signaling.
{"title":"Taoren Honghua Jian improves ferroptosis-mediated myocardial damage following myocardial infarction via Nrf2-dependent enhancement of GPX4/FSP1.","authors":"Guo-Yong Zhang, Feng Zhang, Ling-Peng Xie, Xin Han, Zhi-Xin Wang, Wen-Long Wang, Yan Peng, Hong-Lin Xu, Tong Xu, Ming-Jie Pang, Bin Liu, Dong Wang, Ying-Chun Zhou, Yu-Ting Wu","doi":"10.1093/jpp/rgaf075","DOIUrl":"10.1093/jpp/rgaf075","url":null,"abstract":"<p><strong>Objectives: </strong>Myocardial infarction (MI) remains a leading cause of global mortality, and the inhibition of ferroptosis has cardioprotective potential. Taoren Honghua Jian (TRHHJ) has been used clinically to improve cardiovascular disorders. However, whether TRHHJ inhibits cardiomyocyte ferroptosis and ameliorates myocardial damage after MI requires further investigation. This study aimed to assess the ferroptosis-inhibiting effects of TRHHJ on post-MI myocardial injury and its underlying mechanisms.</p><p><strong>Methods: </strong>In vivo MI models were established via left anterior descending coronary artery ligation, and the cardioprotective effects of TRHHJ were assessed by echocardiography and histopathology combined with ferroptosis biomarker detection and Nrf2 signaling protein analysis. In vitro, erastin induced ferroptosis in H9C2 cells, and the anti-ferroptotic effects of TRHHJ was evaluated using the MTT assay, ferroptosis markers, and Nrf2 signaling analysis. Mechanistically, Nrf2 inhibitor and knockout mice were used for validation.</p><p><strong>Results: </strong>TRHHJ suppressed cardiomyocyte ferroptosis, reduced myocardial damage, and improved cardiac function in post-MI mice by activating the Nrf2 signaling pathway in vivo. TRHHJ enhanced cell viability and inhibited erastin-induced ferroptosis in H9C2 cells by increasing Nrf2 level and activating downstream signaling in vitro. Inhibition or knockout of Nrf2 partially abolished these protective effects.</p><p><strong>Conclusions: </strong>TRHHJ inhibits cardiomyocyte ferroptosis and improves myocardial damage after MI through activation of Nrf2 signaling.</p>","PeriodicalId":16960,"journal":{"name":"Journal of Pharmacy and Pharmacology","volume":" ","pages":"1726-1741"},"PeriodicalIF":3.2,"publicationDate":"2025-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145313259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Omnia F Hassan, Marwa H S Dawoud, Sherine M Ibrahim
Cardiovascular diseases, such as arrhythmia and cardiomyopathy, are leading causes of mortality worldwide. Cardiomyopathy is often triggered by oxidative stress. Objective The current study aims to investigate the therapeutic potential of selenium and iron oxide (FeO) nanoparticles, individually and in combination, in treating doxorubicin (DOX)-induced cardiomyopathy in rats. Method Cardiomyopathy was induced in Wistar rats, where selenium, FeO nanoparticles, or both were formulated and tested on the rat model. Key findings DOX administration revealed a significant elevation in cardiac enzymes: creatinine kinase (CK-MB) and troponin-1 (cTn-1), and elevation of oxidative stress markers, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and malondialdehyde (MDA), together with a reduction in superoxide dismutase (SOD) and glutathione peroxidase (GPx). A significant elevation in inflammatory markers, protein kinase C (PKC), nuclear factor-kappa B (NF-kB), and metalloproteinase-9 (MMP-9), was obvious after DOX administration in rats for induction of cardiomyopathy together with histopathological alterations. Selenium and FeO nanoparticles groups significantly improved oxidative stress, inflammation, and apoptosis compared with the DOX group. Combined selenium and FeO nanoparticle groups showed better results compared with the other treatment groups. Conclusion Selenium and FeO nanoparticles showed potential anti-oxidant, anti-inflammatory and anti-apoptotic effects in the treatment of DOX-induced cardiomyopathy in rats.
心血管疾病,如心律失常和心肌病,是全世界死亡的主要原因。心肌病常由氧化应激引起。目的探讨硒和氧化铁纳米颗粒单独或联合治疗阿霉素(DOX)诱导的大鼠心肌病的治疗潜力。方法分别配制硒、FeO纳米颗粒或两者均配制的Wistar大鼠心肌病模型。DOX处理显示心肌酶:肌酐激酶(CK-MB)和肌钙蛋白-1 (cTn-1)显著升高,氧化应激标志物,烟酰胺腺嘌呤二核苷酸磷酸(NADPH)氧化酶和丙二醛(MDA)升高,同时超氧化物歧化酶(SOD)和谷胱甘肽过氧化物酶(GPx)降低。DOX诱导大鼠心肌病后,炎症标志物蛋白激酶C (PKC)、核因子κ B (NF-kB)和金属蛋白酶9 (MMP-9)明显升高,并伴有组织病理学改变。与DOX组相比,硒和FeO纳米颗粒组可显著改善氧化应激、炎症和细胞凋亡。硒和FeO纳米颗粒联合组与其他处理组相比效果更好。结论硒和FeO纳米颗粒对dox诱导的大鼠心肌病具有潜在的抗氧化、抗炎和抗凋亡作用。
{"title":"Selenium and iron oxide nanoparticles mitigate doxorubicin-induced cardiomyopathy in rats via Nox1/p53 pathway inhibition.","authors":"Omnia F Hassan, Marwa H S Dawoud, Sherine M Ibrahim","doi":"10.1093/jpp/rgaf079","DOIUrl":"https://doi.org/10.1093/jpp/rgaf079","url":null,"abstract":"<p><p>Cardiovascular diseases, such as arrhythmia and cardiomyopathy, are leading causes of mortality worldwide. Cardiomyopathy is often triggered by oxidative stress. Objective The current study aims to investigate the therapeutic potential of selenium and iron oxide (FeO) nanoparticles, individually and in combination, in treating doxorubicin (DOX)-induced cardiomyopathy in rats. Method Cardiomyopathy was induced in Wistar rats, where selenium, FeO nanoparticles, or both were formulated and tested on the rat model. Key findings DOX administration revealed a significant elevation in cardiac enzymes: creatinine kinase (CK-MB) and troponin-1 (cTn-1), and elevation of oxidative stress markers, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and malondialdehyde (MDA), together with a reduction in superoxide dismutase (SOD) and glutathione peroxidase (GPx). A significant elevation in inflammatory markers, protein kinase C (PKC), nuclear factor-kappa B (NF-kB), and metalloproteinase-9 (MMP-9), was obvious after DOX administration in rats for induction of cardiomyopathy together with histopathological alterations. Selenium and FeO nanoparticles groups significantly improved oxidative stress, inflammation, and apoptosis compared with the DOX group. Combined selenium and FeO nanoparticle groups showed better results compared with the other treatment groups. Conclusion Selenium and FeO nanoparticles showed potential anti-oxidant, anti-inflammatory and anti-apoptotic effects in the treatment of DOX-induced cardiomyopathy in rats.</p>","PeriodicalId":16960,"journal":{"name":"Journal of Pharmacy and Pharmacology","volume":"77 12","pages":"1762-1776"},"PeriodicalIF":3.2,"publicationDate":"2025-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145654638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ayla Winnie Ramos da Silva, Lorena Batista da Silva, Douglas Fernando Rambo, Renata Biegelmeyer
Objectives: Natural products (NP) play a crucial role in the development of new compounds, due to their complex chemical structure and pharmacological diversity. Neurodegenerative diseases and other disorders in the central nervous system (CNS) have become a significant problem in the world due to the increase in life expectancy of the elderly population. This increases the risk of developing diseases, such as Parkinson's disease, Huntington's disease, Alzheimer's disease. Therefore, this exploratory review aims to show the applications of zebrafish for NP research and how they can be used in CNS's in vivo studies.
Methods: The present review covers the literature survey until 2023, including the descriptors for zebrafish, natural product and neurodegenerative diseases. The databases used were PubMed, Scopus, Cochrane and Lilacs.
Key findings: For the development of new medicines, an efficient animal model is required, and the zebrafish has stood out as a promising model due to its small size, low cost of maintenance, ease of handling, and transparency of embryos, which allows real-time observation of development and pathological processes. They possess conserved neurotransmission systems such as glutamatergic, cholinergic, dopaminergic, serotonergic, histaminergic, GABAergic, and purinergic pathways, making them especially relevant for modelling CNS disorders. From literature survey, flavonoids, alkaloids, and phenolic compounds were the most frequently studied, indicating that its influence the pathophysiological mechanisms associated with neurodegenerative diseases.
Conclusions: This current review offers data for further research work with natural products aiming treatment for CNS disorders.
{"title":"Application of zebrafish (Danio rerio) as a model organism for central nervous system disorders screening of natural products.","authors":"Ayla Winnie Ramos da Silva, Lorena Batista da Silva, Douglas Fernando Rambo, Renata Biegelmeyer","doi":"10.1093/jpp/rgaf067","DOIUrl":"10.1093/jpp/rgaf067","url":null,"abstract":"<p><strong>Objectives: </strong>Natural products (NP) play a crucial role in the development of new compounds, due to their complex chemical structure and pharmacological diversity. Neurodegenerative diseases and other disorders in the central nervous system (CNS) have become a significant problem in the world due to the increase in life expectancy of the elderly population. This increases the risk of developing diseases, such as Parkinson's disease, Huntington's disease, Alzheimer's disease. Therefore, this exploratory review aims to show the applications of zebrafish for NP research and how they can be used in CNS's in vivo studies.</p><p><strong>Methods: </strong>The present review covers the literature survey until 2023, including the descriptors for zebrafish, natural product and neurodegenerative diseases. The databases used were PubMed, Scopus, Cochrane and Lilacs.</p><p><strong>Key findings: </strong>For the development of new medicines, an efficient animal model is required, and the zebrafish has stood out as a promising model due to its small size, low cost of maintenance, ease of handling, and transparency of embryos, which allows real-time observation of development and pathological processes. They possess conserved neurotransmission systems such as glutamatergic, cholinergic, dopaminergic, serotonergic, histaminergic, GABAergic, and purinergic pathways, making them especially relevant for modelling CNS disorders. From literature survey, flavonoids, alkaloids, and phenolic compounds were the most frequently studied, indicating that its influence the pathophysiological mechanisms associated with neurodegenerative diseases.</p><p><strong>Conclusions: </strong>This current review offers data for further research work with natural products aiming treatment for CNS disorders.</p>","PeriodicalId":16960,"journal":{"name":"Journal of Pharmacy and Pharmacology","volume":" ","pages":"1646-1662"},"PeriodicalIF":3.2,"publicationDate":"2025-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144859266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objectives: Ruxolitinib (Rux), an oral Janus tyrosine Kinase (JAK) tyrosine kinase inhibitor, has demonstrated anti-inflammatory properties and the ability to mitigate denervation-induced skeletal muscle atrophy. Here, we checked the potential efficacy of Rux on cancer cachexia and tried to clarified its mechanisms.
Methods: The in vitro cell models of C26 or LLC CM-induced C2C12 myotubes were used to check the influence of Rux on myotube atrophy. C26 tumour-bearing mice (male BALB/c mice) were applied as the animal model to examine the effects of Rux in attenuating cachexia symptoms. Western blot analysis was utilized to investigate the potential mechanisms of Rux.
Key findings: Rux significantly attenuated C2C12 myotube atrophy in vitro. Rux suppressed the interleukin-6 secretion by inhibiting STAT3 activation in tumour cells and macrophages. The administration of Rux prevented body weight loss and muscle wasting in C26 tumour-bearing mice without affecting tumour growth. At the end of the experiment, mice in the Rux treatment group exhibited a 6.7% increase in body weight compared to the C26 model group. Furthermore, Rux enhanced in gastrocnemius myofibres cross-sectional area and grip strength.
Conclusions: Rux ameliorates cancer cachexia muscle atrophy by inhibiting STAT3/Atrogin-1 signaling. Rux may represent a promising therapeutic candidate for the treatment of cancer cachexia.
{"title":"Ruxolitinib alleviated muscle atrophy in cancer cachexia by inhibiting IL-6/JAK/STAT3 signaling pathway in mice.","authors":"Cong Li, Xiaofan Gu, Zixia Zhu, Xiaojuan Pan, Meng Fan, Xuan Liu, Xiongwen Zhang","doi":"10.1093/jpp/rgaf073","DOIUrl":"10.1093/jpp/rgaf073","url":null,"abstract":"<p><strong>Objectives: </strong>Ruxolitinib (Rux), an oral Janus tyrosine Kinase (JAK) tyrosine kinase inhibitor, has demonstrated anti-inflammatory properties and the ability to mitigate denervation-induced skeletal muscle atrophy. Here, we checked the potential efficacy of Rux on cancer cachexia and tried to clarified its mechanisms.</p><p><strong>Methods: </strong>The in vitro cell models of C26 or LLC CM-induced C2C12 myotubes were used to check the influence of Rux on myotube atrophy. C26 tumour-bearing mice (male BALB/c mice) were applied as the animal model to examine the effects of Rux in attenuating cachexia symptoms. Western blot analysis was utilized to investigate the potential mechanisms of Rux.</p><p><strong>Key findings: </strong>Rux significantly attenuated C2C12 myotube atrophy in vitro. Rux suppressed the interleukin-6 secretion by inhibiting STAT3 activation in tumour cells and macrophages. The administration of Rux prevented body weight loss and muscle wasting in C26 tumour-bearing mice without affecting tumour growth. At the end of the experiment, mice in the Rux treatment group exhibited a 6.7% increase in body weight compared to the C26 model group. Furthermore, Rux enhanced in gastrocnemius myofibres cross-sectional area and grip strength.</p><p><strong>Conclusions: </strong>Rux ameliorates cancer cachexia muscle atrophy by inhibiting STAT3/Atrogin-1 signaling. Rux may represent a promising therapeutic candidate for the treatment of cancer cachexia.</p>","PeriodicalId":16960,"journal":{"name":"Journal of Pharmacy and Pharmacology","volume":" ","pages":"1715-1725"},"PeriodicalIF":3.2,"publicationDate":"2025-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144958411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nan Wang, Jing Li, Ze-Xuan Chen, Jie Tang, Xue-Yee Lim, Ling Li, Tong Zhang
Objectives: Ling Gui Zhu Gan (LGZG) Granules is a marketed traditional Chinese medicine compound granule, which is formulated to be consistent with the key quality attributes of the traditional LGZG Decoction. The volatile components are important parts of its preparation process.
Methods: A high-fat diet (HFD)-induced Non-alcoholic fatty liver disease (NAFLD) mouse model was established to evaluate the therapeutic effects of LGZG and preparation of LGZG's volatile components (IC-LGZG). Gut microbiota composition, Short-chain Fatty Acids (SCFA) levels, and intestinal parameters were assessed, and its correlations were analyzed. Lipopolysaccharide-induced RAW264.7 cells tested anti-inflammatory effects.
Key findings: LGZG and IC-LGZG significantly reduced HFD-induced body weight gain, improved lipid profiles and liver function, restored gut microbiota balance, increased beneficial bacteria (Akkermansia, Bacteroides, Parabacteroides, Dubosiella, and Bifidobacterium) that produce SCFAs, thereby enhancing SCFA concentrations (acetic acid, propionic acid, and butyric acid), decreased harmful bacteria abundance, and strengthened the intestinal barrier. In vitro studies showed that LGZG, IC-LGZG, and cinnamaldehyde exerted anti-inflammatory effects.
Conclusion: LGZG and its volatile components effectively alleviate the progression of NAFLD by modulating the gut microbiota homeostasis and SCFA levels, and can exert anti-inflammatory effects.
{"title":"Intervention of non-alcoholic fatty liver disease by Ling Gui Zhu Gan Granules and its volatile components through the metabolism of intestinal microbiota and short-chain fatty acids.","authors":"Nan Wang, Jing Li, Ze-Xuan Chen, Jie Tang, Xue-Yee Lim, Ling Li, Tong Zhang","doi":"10.1093/jpp/rgaf070","DOIUrl":"10.1093/jpp/rgaf070","url":null,"abstract":"<p><strong>Objectives: </strong>Ling Gui Zhu Gan (LGZG) Granules is a marketed traditional Chinese medicine compound granule, which is formulated to be consistent with the key quality attributes of the traditional LGZG Decoction. The volatile components are important parts of its preparation process.</p><p><strong>Methods: </strong>A high-fat diet (HFD)-induced Non-alcoholic fatty liver disease (NAFLD) mouse model was established to evaluate the therapeutic effects of LGZG and preparation of LGZG's volatile components (IC-LGZG). Gut microbiota composition, Short-chain Fatty Acids (SCFA) levels, and intestinal parameters were assessed, and its correlations were analyzed. Lipopolysaccharide-induced RAW264.7 cells tested anti-inflammatory effects.</p><p><strong>Key findings: </strong>LGZG and IC-LGZG significantly reduced HFD-induced body weight gain, improved lipid profiles and liver function, restored gut microbiota balance, increased beneficial bacteria (Akkermansia, Bacteroides, Parabacteroides, Dubosiella, and Bifidobacterium) that produce SCFAs, thereby enhancing SCFA concentrations (acetic acid, propionic acid, and butyric acid), decreased harmful bacteria abundance, and strengthened the intestinal barrier. In vitro studies showed that LGZG, IC-LGZG, and cinnamaldehyde exerted anti-inflammatory effects.</p><p><strong>Conclusion: </strong>LGZG and its volatile components effectively alleviate the progression of NAFLD by modulating the gut microbiota homeostasis and SCFA levels, and can exert anti-inflammatory effects.</p>","PeriodicalId":16960,"journal":{"name":"Journal of Pharmacy and Pharmacology","volume":" ","pages":"1676-1689"},"PeriodicalIF":3.2,"publicationDate":"2025-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144958299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: To evaluate the clinical efficacy of the topical application of vancomycin powder in the prevention of surgical site infection after total joint arthroplasty (TJA).
Method: Five English-language databases and four Chinese-language databases were systematically searched from the establishment of the database to 31 January 2024, and a meta-analysis was performed using Review Manager 5.3 software.
Results: A total of 34 314 patients from 17 studies were included in this meta-analysis. The results showed that, compared with the control group, the topical application of vancomycin powder in the experimental group reduced the overall incidence of prosthetic joint infection (PJI) after TJA surgery (P < .001). Within the subdivisions of the surgical field, in total knee arthroplasty, the incidence of PJI was significantly lower in the experimental group using vancomycin powder than in the control group not using this powder (P < .001). In total hip arthroplasty, the incidence of PJI was also significantly lower in the experimental group than in the control group (P = .004). However, 11 studies mentioned adverse reactions, and the results showed that the incidence of adverse reactions in the experimental group increased compared with the control group (P = .008).
Conclusion: The application of vancomycin powder appears to significantly reduce PJI risk in TJA patients; however, an increased incidence of postoperative wound complications warrants cautious clinical consideration.
{"title":"Clinical efficacy of topical vancomycin powder in the prevention of surgical site infection in total joint arthroplasty: a systematic review and meta-analysis.","authors":"Jingya Liu, Na Cao, Kuimeng Li, Yan Zhang","doi":"10.1093/jpp/rgaf077","DOIUrl":"10.1093/jpp/rgaf077","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the clinical efficacy of the topical application of vancomycin powder in the prevention of surgical site infection after total joint arthroplasty (TJA).</p><p><strong>Method: </strong>Five English-language databases and four Chinese-language databases were systematically searched from the establishment of the database to 31 January 2024, and a meta-analysis was performed using Review Manager 5.3 software.</p><p><strong>Results: </strong>A total of 34 314 patients from 17 studies were included in this meta-analysis. The results showed that, compared with the control group, the topical application of vancomycin powder in the experimental group reduced the overall incidence of prosthetic joint infection (PJI) after TJA surgery (P < .001). Within the subdivisions of the surgical field, in total knee arthroplasty, the incidence of PJI was significantly lower in the experimental group using vancomycin powder than in the control group not using this powder (P < .001). In total hip arthroplasty, the incidence of PJI was also significantly lower in the experimental group than in the control group (P = .004). However, 11 studies mentioned adverse reactions, and the results showed that the incidence of adverse reactions in the experimental group increased compared with the control group (P = .008).</p><p><strong>Conclusion: </strong>The application of vancomycin powder appears to significantly reduce PJI risk in TJA patients; however, an increased incidence of postoperative wound complications warrants cautious clinical consideration.</p>","PeriodicalId":16960,"journal":{"name":"Journal of Pharmacy and Pharmacology","volume":" ","pages":"1751-1761"},"PeriodicalIF":3.2,"publicationDate":"2025-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145092051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objectives: Chronic kidney disease (CKD) is a progressive medical condition marked by a gradual decline in kidney function, leading to an accumulation of waste products and fluids in the body. Drug-induced liver injury (DILI) poses a significant clinical challenge in CKD management, with paracetamol being a commonly used medication. Advanced oxidation protein products (AOPPs) are biomarkers of CKD progression and contributors to DILI. However, the mechanisms behind the increased incidence of DILI in CKD remain unclear.
Methods: We developed an adenine-induced CKD mice model, a paracetamol-induced DILI mice model, and an AOPPs-loaded mice model using intraperitoneal injections.
Key findings: Declining renal function in the CKD model was associated with a significant weight loss and increased the concentration of serum creatinine and blood urea nitrogen. Following paracetamol administration, the alanine aminotransferase (ALT), aspartate aminotransferase (AST), and N-acetyl-p-benzoquinoneimine and liver tissue necrosis increased significantly in CKD groups. In addition, the expression of cytochrome P450 2E1 (CYP2E1) and thrombospondin receptor (CD36) were upregulated, while the adenylate-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signaling pathway showed significant changes in protein expression and phosphorylation. In AOPPs-loaded model, AOPPs upregulated AMPK and Akt protein expression, along with reduced mTOR levels. In HepG2 and L0-2 cell lines, AOPPs and paracetamol significantly increased the protein expression and phosphorylation of AMPK and Akt, alongside a decreased mTOR expression and phosphorylation. AOPPs and paracetamol significantly induced the apoptosis in HepG2 and L0-2 cells. Notably, the expression of CYP2E1 induced by AOPPs and paracetamol was inhibited by dorsomorphin and corynoxine B.
Conclusions: These findings suggest that the AMPK-mTOR signaling pathway mediates the worsening of paracetamol-induced liver injury in CKD, with AOPPs potentially serving as key endogenous factors. This study lays the groundwork for identifying crucial molecules involved in exacerbated paracetamol-induced liver injury in CKD, which may serve as new drug targets and improve the safety profile of paracetamol in patients with CKD.
{"title":"Advanced oxidation protein products accelerates paracetamol-induced liver injury through AMPK-mTOR signaling pathway in chronic kidney disease.","authors":"Sui Wei, Huanhuan Liu, Zixi Hong, Mimi Zhang, Zhufen Lin, Haixing Feng, Xiaokang Wang, Jingqian Zhao, Xixiao Yang, Tianrong Xun","doi":"10.1093/jpp/rgaf069","DOIUrl":"10.1093/jpp/rgaf069","url":null,"abstract":"<p><strong>Objectives: </strong>Chronic kidney disease (CKD) is a progressive medical condition marked by a gradual decline in kidney function, leading to an accumulation of waste products and fluids in the body. Drug-induced liver injury (DILI) poses a significant clinical challenge in CKD management, with paracetamol being a commonly used medication. Advanced oxidation protein products (AOPPs) are biomarkers of CKD progression and contributors to DILI. However, the mechanisms behind the increased incidence of DILI in CKD remain unclear.</p><p><strong>Methods: </strong>We developed an adenine-induced CKD mice model, a paracetamol-induced DILI mice model, and an AOPPs-loaded mice model using intraperitoneal injections.</p><p><strong>Key findings: </strong>Declining renal function in the CKD model was associated with a significant weight loss and increased the concentration of serum creatinine and blood urea nitrogen. Following paracetamol administration, the alanine aminotransferase (ALT), aspartate aminotransferase (AST), and N-acetyl-p-benzoquinoneimine and liver tissue necrosis increased significantly in CKD groups. In addition, the expression of cytochrome P450 2E1 (CYP2E1) and thrombospondin receptor (CD36) were upregulated, while the adenylate-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signaling pathway showed significant changes in protein expression and phosphorylation. In AOPPs-loaded model, AOPPs upregulated AMPK and Akt protein expression, along with reduced mTOR levels. In HepG2 and L0-2 cell lines, AOPPs and paracetamol significantly increased the protein expression and phosphorylation of AMPK and Akt, alongside a decreased mTOR expression and phosphorylation. AOPPs and paracetamol significantly induced the apoptosis in HepG2 and L0-2 cells. Notably, the expression of CYP2E1 induced by AOPPs and paracetamol was inhibited by dorsomorphin and corynoxine B.</p><p><strong>Conclusions: </strong>These findings suggest that the AMPK-mTOR signaling pathway mediates the worsening of paracetamol-induced liver injury in CKD, with AOPPs potentially serving as key endogenous factors. This study lays the groundwork for identifying crucial molecules involved in exacerbated paracetamol-induced liver injury in CKD, which may serve as new drug targets and improve the safety profile of paracetamol in patients with CKD.</p>","PeriodicalId":16960,"journal":{"name":"Journal of Pharmacy and Pharmacology","volume":" ","pages":"1663-1675"},"PeriodicalIF":3.2,"publicationDate":"2025-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Qian Li, Hao Xie, Linli Li, Wenying Yan, Guoqiang Liu
Objectives: To investigate the antitumor effects of aucubin (AC) in non-small cell lung cancer (NSCLC) and uncover its plausible mechanism against lung cancer stem-like cells (LCSCs).
Methods: In vitro experiments included MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a reagent commonly used for cell viability assay) and colony formation assays to assess anti-proliferative effects on A549 and NCI-H1975 lung cancer cell lines, wound healing and Transwell invasion assays to evaluate inhibition of cell migration and invasion, tumorsphere-formation experiments to detect changes in NSCLC cell stemness, as well as Western blot and quantitative reverse transcription polymerase chain reaction (qRT-PCR) analyses to measure the expression of LCSC markers (CD44, CD133, Oct4, and Nanog). In vivo experiments were conducted to observe the impact of AC on NSCLC metastasis and mouse survival rates. Further mechanistic studies involved transcriptomic gene set enrichment analysis, Western blot, qRT-PCR, molecular docking, and Surface Plasmon Resonance (SPR) methods to investigate how AC directly targets β-catenin and promotes its ubiquitin-mediated degradation.
Key findings: AC exerted significant anti-proliferative effects on A549 and NCI-H1975 cells, inhibited cancer cell migration and invasion, reduced the stemness of NSCLC cells, and markedly downregulated the expression of LCSC markers in vitro. In vivo, AC treatment significantly reduced NSCLC metastasis and improved mouse survival rates.Mechanistically, AC blocked the WNT (Wingless-related integration site, a family of secreted lipid-modified signaling glycoproteins that play crucial roles in embryonic development, tissue homeostasis, and regeneration) signaling pathway by downregulating β-catenin and c-Myc expression. It directly targeted β-catenin, promoting its degradation via the ubiquitin-proteasome pathway.
Conclusions: This study uncovers a novel anti-LCSC mechanism of AC, offers alternative strategies for NSCLC treatment, and provides innovative lead compounds for the development of drugs targeting lung cancer stem cells.
{"title":"Aucubin inhibits the activity of lung cancer stem-like cells by targeting degradation of β-catenin.","authors":"Qian Li, Hao Xie, Linli Li, Wenying Yan, Guoqiang Liu","doi":"10.1093/jpp/rgaf081","DOIUrl":"10.1093/jpp/rgaf081","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the antitumor effects of aucubin (AC) in non-small cell lung cancer (NSCLC) and uncover its plausible mechanism against lung cancer stem-like cells (LCSCs).</p><p><strong>Methods: </strong>In vitro experiments included MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a reagent commonly used for cell viability assay) and colony formation assays to assess anti-proliferative effects on A549 and NCI-H1975 lung cancer cell lines, wound healing and Transwell invasion assays to evaluate inhibition of cell migration and invasion, tumorsphere-formation experiments to detect changes in NSCLC cell stemness, as well as Western blot and quantitative reverse transcription polymerase chain reaction (qRT-PCR) analyses to measure the expression of LCSC markers (CD44, CD133, Oct4, and Nanog). In vivo experiments were conducted to observe the impact of AC on NSCLC metastasis and mouse survival rates. Further mechanistic studies involved transcriptomic gene set enrichment analysis, Western blot, qRT-PCR, molecular docking, and Surface Plasmon Resonance (SPR) methods to investigate how AC directly targets β-catenin and promotes its ubiquitin-mediated degradation.</p><p><strong>Key findings: </strong>AC exerted significant anti-proliferative effects on A549 and NCI-H1975 cells, inhibited cancer cell migration and invasion, reduced the stemness of NSCLC cells, and markedly downregulated the expression of LCSC markers in vitro. In vivo, AC treatment significantly reduced NSCLC metastasis and improved mouse survival rates.Mechanistically, AC blocked the WNT (Wingless-related integration site, a family of secreted lipid-modified signaling glycoproteins that play crucial roles in embryonic development, tissue homeostasis, and regeneration) signaling pathway by downregulating β-catenin and c-Myc expression. It directly targeted β-catenin, promoting its degradation via the ubiquitin-proteasome pathway.</p><p><strong>Conclusions: </strong>This study uncovers a novel anti-LCSC mechanism of AC, offers alternative strategies for NSCLC treatment, and provides innovative lead compounds for the development of drugs targeting lung cancer stem cells.</p>","PeriodicalId":16960,"journal":{"name":"Journal of Pharmacy and Pharmacology","volume":" ","pages":"1777-1786"},"PeriodicalIF":3.2,"publicationDate":"2025-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145030185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xiaolian Liu, Jijiao Wu, Bolin Zhao, Lin Wen, Chuipeng Liang, Zihao Sun, Jia Luo, Xiaofang Li
Objectives: Dendrobium officinale has been used as a medicinal and edible plant for more than 2000 years. It was often used by the ancients to nourish the body, brew baijiu and brew tea. The review's objective was to examine the traditional uses, agricultural technology, processing, chemical composition, pharmacological mechanisms (in vitro/vivo), toxicology, and applications of D. officinale conducted over the past 10 years.
Methods: Using online databases including Web of Science, PubMed, Google Scholar, and CNKI, the following search phrases were used to look for the data: D. officinale, D. officinale Kimura et Migo, pharmacology, and toxicology. All studies on the genus from 2014 to 2025 were included in this review.
Key findings: Numerous reports indicate that the biological activity of D. officinale are diverse and include hepatoprotective properties, immunomodulatory effects, antioxidant properties, therapy of metabolic syndrome, anticancer properties, and improvement of gastrointestinal function. D. officinale is considered to have minimal toxicity, and is currently predominantly marketed as a dietary supplement.
Conclusions: D. officinale has the potential to be developed and utilized in the fields of medicine, health care, and regimen. It is recommended that clinical studies on D. officinale be expanded to ascertain its safety and efficacy for human use.
目的:铁皮石斛作为药用和食用植物已有2000多年的历史。古人经常用它来滋补身体,酿造白酒和泡茶。该综述的目的是审查过去10年来对铁皮石斛的传统用途、农业技术、加工、化学成分、药理学机制(体外/体内)、毒理学和应用的研究。方法:采用Web of Science、PubMed、谷歌Scholar、CNKI等在线数据库,检索词为:D. officinale、D. officinale Kimura et Migo、pharmacology、toxicology。本综述纳入了2014年至2025年关于该属的所有研究。主要发现:大量报道表明,铁皮鸡的生物活性是多种多样的,包括肝保护特性、免疫调节作用、抗氧化特性、治疗代谢综合征、抗癌特性和改善胃肠道功能。D. officinale被认为毒性最小,目前主要作为膳食补充剂销售。结论:officinale在医学、保健、养生等领域具有开发利用的潜力。建议扩大对D. officinale的临床研究,以确定其对人类使用的安全性和有效性。
{"title":"Dendrobium officinale Kimura et Migo: traditional uses, agricultural technology, processing, chemical composition, pharmacological mechanisms, toxicology, and applications.","authors":"Xiaolian Liu, Jijiao Wu, Bolin Zhao, Lin Wen, Chuipeng Liang, Zihao Sun, Jia Luo, Xiaofang Li","doi":"10.1093/jpp/rgaf074","DOIUrl":"10.1093/jpp/rgaf074","url":null,"abstract":"<p><strong>Objectives: </strong>Dendrobium officinale has been used as a medicinal and edible plant for more than 2000 years. It was often used by the ancients to nourish the body, brew baijiu and brew tea. The review's objective was to examine the traditional uses, agricultural technology, processing, chemical composition, pharmacological mechanisms (in vitro/vivo), toxicology, and applications of D. officinale conducted over the past 10 years.</p><p><strong>Methods: </strong>Using online databases including Web of Science, PubMed, Google Scholar, and CNKI, the following search phrases were used to look for the data: D. officinale, D. officinale Kimura et Migo, pharmacology, and toxicology. All studies on the genus from 2014 to 2025 were included in this review.</p><p><strong>Key findings: </strong>Numerous reports indicate that the biological activity of D. officinale are diverse and include hepatoprotective properties, immunomodulatory effects, antioxidant properties, therapy of metabolic syndrome, anticancer properties, and improvement of gastrointestinal function. D. officinale is considered to have minimal toxicity, and is currently predominantly marketed as a dietary supplement.</p><p><strong>Conclusions: </strong>D. officinale has the potential to be developed and utilized in the fields of medicine, health care, and regimen. It is recommended that clinical studies on D. officinale be expanded to ascertain its safety and efficacy for human use.</p>","PeriodicalId":16960,"journal":{"name":"Journal of Pharmacy and Pharmacology","volume":" ","pages":"1611-1645"},"PeriodicalIF":3.2,"publicationDate":"2025-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144958313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Correction to: Icariside I reduces breast cancer proliferation, apoptosis, invasion and metastasis probably through inhibiting IL-6/STAT3 signaling pathway.","authors":"","doi":"10.1093/jpp/rgaf122","DOIUrl":"https://doi.org/10.1093/jpp/rgaf122","url":null,"abstract":"","PeriodicalId":16960,"journal":{"name":"Journal of Pharmacy and Pharmacology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145635164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}